Oracle’s $553B Backlog Soars 325%! 03/21/26
/
RSS Feed
Oracle’s $553B Backlog Soars 325%! 03/21/26
Key Stories:
- Oracle, the enterprise software and cloud computing giant, just dropped a bombshell with its fiscal third-quarter earnings report, revealing an astounding $553 billion in remaining purchase obligations. That’s a jaw-dropping 325% increase year-over-year. This immense backlog, largely driven by demand for its cloud infrastructure services, is being interpreted by many as a powerful validation of its long-term growth trajectory and a sign that its strategic investments are yielding substantial future revenue commitments. Read more
- Digging deeper into Oracle’s impressive numbers, that $553 billion backlog isn’t just a headline figure; it’s seen as a strong indicator that the company’s aggressive pivot into cloud computing and its strategic investments in artificial intelligence infrastructure are truly paying off. This massive surge in future commitments, up 325% from a year ago, essentially answers the question of whether this backlog is a ‘gold mine’ or a ‘mirage,’ firmly putting it in the ‘gold mine’ camp following their earnings. The market is clearly recognizing Oracle’s increasing relevance in the booming AI and enterprise cloud space. Read more
- Shifting gears to the biotech sector, Monte Rosa Therapeutics, ticker GLUE, is making waves with a significant new supply agreement. The company announced it’s partnering with pharmaceutical giant Johnson & Johnson to evaluate MRT-2359, Monte Rosa’s experimental drug, alongside J&J’s ERLEADA in a Phase 2 trial for metastatic castration-resistant prostate cancer. This collaboration comes on the heels of additional positive clinical data for MRT-2359 presented at ASCO GU 2026, bolstering confidence in its potential. Monte Rosa shares are currently trading around $15.63, having delivered an impressive 169.5% return over the past year, underscoring investor enthusiasm for its pipeline and strategic partnerships in this crucial therapeutic area. Read more
Keywords: AI, ERLEADA, GLUE, JNJ, Johnson & Johnson, MRT-2359, Monte Rosa Therapeutics, ORCL, Oracle, Phase 2 trial, artificial intelligence, backlog, biotech, clinical data, cloud computing, cloud infrastructure, earnings, enterprise software, growth trajectory, investor confidence, pharmaceutical, prostate cancer, purchase obligations, revenue, strategic investments, supply agreement